Cargando…

Growth differentiation factor 15 is increased in stable MS

OBJECTIVE: To assess whether serum concentrations of the anti-inflammatory cytokine growth differentiation factor 15 (GDF-15) differ in patients with highly active multiple sclerosis (MS) vs patients with stable MS and healthy controls (HCs). METHODS: GDF-15 concentrations were measured by ELISA in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amstad, Andrea, Coray, Mali, Frick, Corina, Barro, Christian, Oechtering, Johanna, Amann, Michael, Wischhusen, Jörg, Kappos, Ludwig, Naegelin, Yvonne, Kuhle, Jens, Mehling, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051204/ https://www.ncbi.nlm.nih.gov/pubmed/32024796 http://dx.doi.org/10.1212/NXI.0000000000000675

Ejemplares similares

Monitoring of radiologic disease activity by serum neurofilaments in MS
por: Uher, Tomas, et al.
Publicado: (2020)

Fingolimod in children with Rett syndrome: the FINGORETT study
por: Naegelin, Yvonne, et al.
Publicado: (2021)

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
por: Fischer-Barnicol, Bettina, et al.
Publicado: (2020)

Central nervous system atrophy predicts future dynamics of disability progression in a real‐world multiple sclerosis cohort
por: Tsagkas, Charidimos, et al.
Publicado: (2021)

Impact of complement activation on clinical outcomes in multiple sclerosis
por: Keller, Christian W., et al.
Publicado: (2021)

Classification of multiple sclerosis based on patterns of CNS regional atrophy covariance
por: Tsagkas, Charidimos, et al.
Publicado: (2021)

Individual Assessment of Brain Tissue Changes in MS and the Effect of Focal Lesions on Short-Term Focal Atrophy Development in MS: A Voxel-Guided Morphometry Study
por: Fox, Jan, et al.
Publicado: (2016)

Death Anxiety and Attitudes towards Death in Patients with Multiple Sclerosis: An Exploratory Study
por: Francalancia, Jara, et al.
Publicado: (2021)

Brain atrophy measurement over a MRI scanner change in multiple sclerosis
por: Sinnecker, Tim, et al.
Publicado: (2022)

Xenogeneic Neu5Gc and self-glycan Neu5Ac epitopes are potential immune targets in MS
por: Boligan, Kayluz F., et al.
Publicado: (2020)

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
por: Kuhle, Jens, et al.
Publicado: (2019)

Avidity of vaccine-induced influenza IgG fails to increase in fingolimod-treated patients with MS
por: Mehling, Matthias, et al.
Publicado: (2014)

Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high‐dose pharmaceutical‐grade biotin (MD1003)
por: Collongues, Nicolas, et al.
Publicado: (2020)

Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study
por: Woelfle, Tim, et al.
Publicado: (2022)

Hepatitis E virus infections in patients with MS on oral disease-modifying treatment
por: Diebold, Martin, et al.
Publicado: (2019)

Longitudinal patterns of cortical thinning in multiple sclerosis
por: Tsagkas, Charidimos, et al.
Publicado: (2020)

Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients
por: Parmar, Katrin, et al.
Publicado: (2021)

Practice Effects of Mobile Tests of Cognition, Dexterity, and Mobility on Patients With Multiple Sclerosis: Data Analysis of a Smartphone-Based Observational Study
por: Woelfle, Tim, et al.
Publicado: (2021)

Determination of CSF GFAP, CCN5, and vWF Levels Enhances the Diagnostic Accuracy of Clinically Defined MS From Non-MS Patients With CSF Oligoclonal Bands
por: Probert, Fay, et al.
Publicado: (2022)

Corrigendum: Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands
por: Probert, Fay, et al.
Publicado: (2022)

Measuring and Validating the Levels of Brain-Derived Neurotrophic Factor in Human Serum
por: Naegelin, Yvonne, et al.
Publicado: (2018)

Wearable Sensor Technologies to Assess Motor Functions in People With Multiple Sclerosis: Systematic Scoping Review and Perspective
por: Woelfle, Tim, et al.
Publicado: (2023)

Longitudinal changes of deep gray matter shape in multiple sclerosis
por: Tsagkas, Charidimos, et al.
Publicado: (2022)

Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis
por: Cagol, Alessandro, et al.
Publicado: (2023)

Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS
por: Oechtering, Johanna, et al.
Publicado: (2022)

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
por: Rust, Heiko, et al.
Publicado: (2016)

Cerebellar Abnormalities Contribute to Disability Including Cognitive Impairment in Multiple Sclerosis
por: Weier, Katrin, et al.
Publicado: (2014)

Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint
por: Wischhusen, Jörg, et al.
Publicado: (2020)

Nano-scale microfluidics to study 3D chemotaxis at the single cell level
por: Frick, Corina, et al.
Publicado: (2018)

Plasma proteome in multiple sclerosis disease progression
por: Malekzadeh, Arjan, et al.
Publicado: (2019)

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis
por: Disanto, Giulio, et al.
Publicado: (2017)

Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS
por: Kuhle, Jens, et al.
Publicado: (2021)

Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study
por: Pless, Silvan, et al.
Publicado: (2023)

Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS
por: Lokhande, Hrishikesh, et al.
Publicado: (2022)

Levels of brain‐derived neurotrophic factor in patients with multiple sclerosis
por: Naegelin, Yvonne, et al.
Publicado: (2020)

Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15
por: Kappos, Ludwig, et al.
Publicado: (2015)

Neurofilament light chain predicts disease activity in relapsing-remitting MS
por: Varhaug, Kristin N., et al.
Publicado: (2017)

Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial
por: Kuhle, Jens, et al.
Publicado: (2023)

Improved Characterization of Visual Evoked Potentials in Multiple Sclerosis by Topographic Analysis
por: Hardmeier, Martin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_n09jcapscql5l43e0050fehls4